- Home
- ARMP vs BOLD Comparison
ARMP vs BOLD Comparison
Compare ARMP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- BOLD
- Stock Information
- Founded
- ARMP N/A
- BOLD 2018
- Country
- ARMP United States
- BOLD United States
- Employees
- ARMP N/A
- BOLD N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- BOLD
- Sector
- ARMP Health Care
- BOLD
- Exchange
- ARMP Nasdaq
- BOLD Nasdaq
- Market Cap
- ARMP 80.0M
- BOLD 81.0M
- IPO Year
- ARMP N/A
- BOLD 2024
- Fundamental
- Price
- ARMP $2.72
- BOLD $3.24
- Analyst Decision
- ARMP Strong Buy
- BOLD Strong Buy
- Analyst Count
- ARMP 1
- BOLD 3
- Target Price
- ARMP $7.00
- BOLD $23.00
- AVG Volume (30 Days)
- ARMP 8.3K
- BOLD 60.3K
- Earning Date
- ARMP 11-13-2024
- BOLD 11-07-2024
- Dividend Yield
- ARMP N/A
- BOLD N/A
- EPS Growth
- ARMP N/A
- BOLD N/A
- EPS
- ARMP N/A
- BOLD N/A
- Revenue
- ARMP $3,719,000.00
- BOLD N/A
- Revenue This Year
- ARMP N/A
- BOLD N/A
- Revenue Next Year
- ARMP $83.33
- BOLD N/A
- P/E Ratio
- ARMP N/A
- BOLD N/A
- Revenue Growth
- ARMP N/A
- BOLD N/A
- 52 Week Low
- ARMP $1.93
- BOLD $2.82
- 52 Week High
- ARMP $4.48
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- ARMP 67.03
- BOLD N/A
- Support Level
- ARMP $2.21
- BOLD N/A
- Resistance Level
- ARMP $2.96
- BOLD N/A
- Average True Range (ATR)
- ARMP 0.15
- BOLD 0.00
- MACD
- ARMP 0.05
- BOLD 0.00
- Stochastic Oscillator
- ARMP 68.42
- BOLD 0.00
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.